SHANGHAI, China, Apr 29, 2025, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the investigator-initiated trial of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of newly diagnosed multiple myeloma (NDMM) (NCT06407947) has been accepted for poster presentation at the 30th Annual Congress of the European Hematology Association (“EHA”). Abstract and further details will be announced after May 14, 2025, at 15:30 CEST.
About CT071
CT071 is a CAR T-cell therapy candidate developed utilizing the proprietary CARcelerate® platform of CARsgen targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma or relapsed/refractory plasma cell leukemia (PCL). An investigator-initiated trial (NCT05838131) is ongoing in China to evaluate the preliminary safety and efficacy of CT071 for the treatment of relapsed/refractory multiple myeloma or plasma cell leukemia. Another investigator-initiated trial (NCT06407947) is ongoing in China for the treatment of newly diagnosed multiple myeloma (NDMM). CT071 received IND clearance from the FDA for the treatment of patients with relapsed/refractory MM or relapsed/refractory primary PCL.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
Contact CARsgen
For more information, please visit https://www.carsgen.com/
Public Relations: PR@carsgen.com
Investor Relations: IR@carsgen.com